XML 23 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 31, 2025
Jun. 30, 2024
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Amendment Flag false    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol HURA    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Registrant Name TuHURA Biosciences, Inc. NV,    
Entity Central Index Key 0001498382    
Current Fiscal Year End Date --12-31    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Public Float     $ 14,932,000
Entity Common Stock, Shares Outstanding   43,680,397  
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Incorporation, State or Country Code NV    
Entity File Number 001-39473    
Entity Tax Identification Number 99-0360497    
Entity Address, Address Line One 10500 University Center Dr.    
Entity Address, Address Line Two Suite 110    
Entity Address, City or Town Tampa    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33612    
City Area Code 813    
Local Phone Number 875-6600    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Name Cherry Bekaert LLP    
Auditor Location Tampa, Florida    
Auditor Firm ID 677    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of TuHURA Biosciences, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ (deficit) equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.